

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

Vero RCB 10-87

RRID:CVCL_JF53

Type: Cell Line

Proper Citation

ECACC Cat# 88020401, RRID:CVCL_JF53

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_JF53

Proper Citation: ECACC Cat# 88020401, RRID:CVCL_JF53

Description: Cell line Vero RCB 10-87 is a Spontaneously immortalized cell line with a species of origin Chlorocebus sabaeus (Green monkey)

Sex: Female

Defining Citation: [PMID:10494966](#), [PMID:19016439](#), [PMID:34417462](#), [PMID:37680537](#)

Comments: Characteristics: A World Health Organisation (WHO) working cell bank of 1000 ampoules deposited at ECACC, derived from an original American Type Culture Collection (ATCC) ampoule. Available free of charge to organisations producing vaccines following receipt of approval to supply from WHO (ECACC=88020401)., Group: Vaccine production cell line., Group: Non-human primate cell line.

Category: Spontaneously immortalized cell line

Organism: Chlorocebus sabaeus (Green monkey)

Name: Vero RCB 10-87

Synonyms: Vero (WHO), Vero(WHO), Vero-WHO, WHO Vero RCB 10-87, WHO Vero 10-87, 10-87 Vero

Cross References: BioSample:SAMN15458746, ECACC:88020401, Wikidata:Q54993052

ID: CVCL_JF53

Vendor: ECACC

Catalog Number: 88020401

Hierarchy: cvcl_0059

Record Creation Time: 20220427T221708+0000

Record Last Update: 20260904T015942+0000

Ratings and Alerts

No rating or validation information has been found for Vero RCB 10-87.

No alerts have been found for Vero RCB 10-87.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Park K, et al. (2026) KLS-3021: Innovative oncolytic virotherapy for the treatment of advanced primary and metastatic cutaneous squamous cell carcinoma. Molecular therapy. Oncology, 34(2), 201182.

Genoyer E, et al. (2025) Exposure of negative-sense viral RNA in the cytoplasm initiates innate immunity to West Nile virus. Molecular cell, 85(6), 1147.

Offersgaard A, et al. (2024) An inactivated SARS-CoV-2 vaccine based on a Vero cell culture-adapted high-titer virus confers cross-protection in small animals. Scientific reports, 14(1), 17039.

Deliyannis G, et al. (2023) Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine. EBioMedicine, 92, 104574.

Rommel JL, et al. (2021) Diverse contributions of avidity to the broad neutralization of Dengue virus by antibodies targeting the E dimer epitope. Virology, 559, 57.

Frei JC, et al. (2018) Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice. Journal of virology, 92(18).

Hoffmann HH, et al. (2017) Diverse Viruses Require the Calcium Transporter SPCA1 for Maturation and Spread. Cell host & microbe, 22(4), 460.